Abstract: The present invention provides compositions and methods for diagnostic imaging. The composition comprises micelles having an outer shell comprising one or more polymer-flavonoid conjugates, optionally an inner shell comprising one or more flavonoid oligomer, and a diagnostic imaging agent encapsulated within the shells. The present invention also provides methods for performing diagnostic imaging using the compositions.

Abstract: The present invention provides a conjugate comprising: (a) a cardiovascular disease (CVD)-targeting ligand, (b) a hydrophilic polymer of polyethylene glycol (PEG), polylactic acid (PLA), polylactic-co-glycolic acid (PLGA), or dextran, and (c) a flavonoid. The present invention also provides to a micelle nanoparticle composition comprising: (a) an outer shell comprising the conjugate, optionally (b) an inner shell comprising oligomeric (?)-epigallocatechin gallate (OEGCG), and optionally (c) a CVD-treating molecule encapsulated in the inner shell. The present invention further provides a method for treating a CVD by administering an effective amount of the present nanoparticle composition to a subject. The CVD-targeting ligand targets the heart tissue and delivers active ingredients to heart tissue for treating cardiovascular diseases or conditions.

Abstract: The present invention provides a conjugate comprising: (a) a CNS-targeting ligand, (b) a hydrophilic polymer of polyethylene glycol (PEG), polylactic acid (PLA), polylactic-co-glycolic acid (PLGA), or dextran, and (c) a flavonoid. The present invention also provides to a micelle nanoparticle composition comprising: (a) an outer shell comprising the conjugate, optionally (b) an inner shell comprising oligomeric (?)-epigallocatechin gallate (OEGCG), and optionally (c) a CNS disease-treating molecule encapsulated in the inner shell. The present invention further provides a method for treating a CNS disease by administering an effective amount of the present nanoparticle composition to a subject. The CNS-targeting ligand targets the CNS tissue and delivers active ingredients to CNS tissue for treating the CNS pathogenic conditions.

Abstract: The present invention provides a method of treating an infectious disease. The method comprises the step of administering to a subject in need thereof an effective amount of (i) a polymer-flavonoid conjugate, (ii) a flavonoid oligomer, or (iii) micelles having a shell formed by one or more polymer-flavonoid conjugates or one or more flavonoid oligomers, or the combination thereof, and having an agent encapsulated within the shell. The present method is effective to treat viral infection, e.g., severe acute respiratory syndrome coronavirus (SARS-CoV), enterovirus virus, HIV, hepatitis B virus, MERS-CoV, influenza virus, Dengue virus, respiratory syncytial virus, hepatitis C virus, monkeypox virus, human papillomavirus, methicillin-resistant Staphylococcus aureus, Pseudomonas, tuberculosis, Bacillus anthracis, Tetani bacterium, Streptococcus pneumoniae, meningococcus, Escherichia coli, Legionella, Neisseria gonorrhea, Neisseria meningitidis, and Salmonella.

Abstract: The present invention provides a method of treating an autoimmune disease including type 1 diabetes, inflammatory bowel disease, rheumatoid arthritis. multiple sclerosis, systemic lupus erythematosus, psoriasis, myasthenia Gravis, and Hashimoto's thyroiditis. The method comprises the step of administering to a subject in need thereof an effective amount of micelles having an outer shell comprising one or more polymer-flavonoid conjugates, optionally an inner shell comprising one or more flavonoid oligomer, and a drug encapsulated within the shells. The present invention also provides a method of treating an autoimmune disease by administering to a subject in need thereof an effective amount of one or more polymer-flavonoid conjugate or one or more flavonoid oligomers.

Abstract: The present invention provides a conjugate comprising: (a) a cancer-targeting ligand, (b) a hydrophilic polymer of polyethylene glycol (PEG), polylactic acid (PLA), polylactic-co-glycolic acid (PLGA), or dextran, and (c) a flavonoid. The present invention also provides to a micelle nanoparticle composition comprising: (a) an outer shell comprising the conjugate, (b) an inner shell comprising oligomeric (?)-epigallocatechin gallate (OEGCG), and optionally (c) a cancer-treating molecule encapsulated in the inner shell. In one embodiment, the nanoparticle composition has at least 70% of the nanoparticles with a diameter between 20-500 nm or 50-300 nm, and one single major peak in the size distribution. The present invention further provides a method for treating cancer by administering an effective amount of the present nanoparticle composition to a subject. The cancer-targeting ligand targets the tumor and delivers active ingredients to tumor for treating cancer.

Abstract: The present invention provides a method of preventing or treating CNS diseases. The method comprises the step of administering to a subject in need thereof an effective amount of (i) a polymer-flavonoid conjugate, (ii) a flavonoid oligomer, or (iii) micelles having an outer shell comprising one or more polymer-flavonoid conjugates and optionally an inner shell comprising one or more flavonoid oligomer and a drug encapsulated within the shells. The present method brings therapeutic effective materials through blood-brain barrier to treat CNS diseases. The present method is effective to treat CNS diseases such as brain tumors, stroke, neurodegenerative diseases.

Abstract: The present disclosure provides a method for treating Alzheimer's disease including the following steps. An effective amount of nano-micro magnetic stir bars is administered to a tissue of a subject suffered from Alzheimer's disease. A rotating magnetic field is provided to the subject, wherein each of the nano-micro magnetic stir bars rotates in the tissue correspondingly to the rotating magnetic field. A reacting step is performed for a reaction time, wherein the tissue generates a rotating microflow corresponding to a rotation of each of the nano-micro magnetic stir bars, and a plurality of amyloids are moved within the tissue along with the rotating microflow and then aggregate so as to form a plurality of amyloid aggregates. A removing step is performed, wherein the amyloid aggregates are captured and collected by phagocytes of the tissue so as to be removed from the tissue of the subject.